Merck

MERCK NEWSROOM (124 press releases)

Advanced Filtering & Sorting Options:

New cosmetic ingredient by Merck to help the skin maintain the integrity of the epidermis

PRESS RELEASE -- 11, October 2021

New product specifically for the needs of aging skin Essential calcium improves overall skin integrity Halal-certified blend of 100% of plant and mineral origin serves sustainable market trends (PRESS RELEASE) DARMSTADT, 11-Oct-2021 — /EuropaWire/ — Merck (ETR: MRK), a German … Read the full press release

AstraZeneca: Exciting ROpel Phase III trial results demonstrate the potential for Lynparza with abiraterone to become a new 1st-line option for patients with metastatic castration-resistant prostate cancer

PRESS RELEASE -- 24, September 2021

(PRESS RELEASE) CAMBRIDGE, 24-Sep-2021 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British–Swedish multinational pharmaceutical and biopharmaceutical company, has announced positive high-level results from the PROpel Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone demonstrated a … Read the full press release

Leadership changes at Merck Electronics: Dorothea Wenzel, Jeff White and Katherine Dei Cas

PRESS RELEASE -- 6, August 2021

(PRESS RELEASE) DARMSTADT, 6-Aug-2021 — /EuropaWire/ — The Merck Group (ETR: MRK), a German multinational science and technology company, has announced some leadership changes within its business sector Electronics. Effective September 1, 2021, Jeff White, currently Head of Delivery Systems … Read the full press release

Merck and Inbrain Neuroelectronics to collaborate on next generation of graphene-based bioelectronic therapies for targeted treatment of chronic diseases

PRESS RELEASE -- 8, July 2021

Innovation Center project of Merck aims to develop smart neurostimulators for targeted treatment of chronic diseases Second collaboration within the Bioelectronics innovation field of Merck focuses on increasing the selectivity and power efficiency of the device to enable energy intensive … Read the full press release

Kuehne+Nagel takes responsibility of global distribution of Covid-19 Vaccine Moderna

PRESS RELEASE -- 7, January 2021

New arrangement leverages Kuehne+Nagel’s global solutions for pharma & healthcare logistics (PRESS RELEASE) CAMBRIDGE, MA, U.S.A. / SCHINDELLEGI, 7-Jan-2021 — /EuropaWire/ — Global transport and logistics company Kuehne+Nagel announces international supply chain arrangement with Moderna, Inc. (NASDAQ:MRNA), a biotechnology company … Read the full press release

AstraZeneca to present updates and developments on promising new medicines for breast cancer at the 2020 San Antonio Breast Cancer Symposium

PRESS RELEASE -- 3, December 2020

New data from the DESTINY-Breast01 Phase II trial reinforce the efficacy of Enhertu in HER2-positive metastatic breast cancer New data from the SERENA-1 Phase I trial show strong efficacy and safety profile for next-generation oral SERD AZD9833 in HR-positive advanced … Read the full press release

Bayer names their new Information and Digital Transformation Chief

PRESS RELEASE -- 24, January 2020

(PRESS RELEASE) LEVERKUSEN, 24-Jan-2020 — /EuropaWire/ — Pharmaceutical company, Bayer, appoints Bijoy Sagar as their new Chief Information and Digital Transformation Officer (CIDO). Sagar, 50, will take over the CIDO position effective in June 2020. Sagar will assume the said … Read the full press release

The best chemical start-up of 2018 Sponsh develops a temperature-sensitive textile which produces water from the air

PRESS RELEASE -- 6, December 2018

EINDHOVEN, 06-Dec-2018 — /EuropaWire/ — Sponsh, an Eindhoven University of Technology spin-off that develops a temperature-sensitive textile which produces water from the air, has been voted the best chemical start-up of 2018. It is the third consecutive year that a TU/e … Read the full press release

Merck completes the sale of its Consumer Health business to Procter & Gamble (P&G)

PRESS RELEASE -- 4, December 2018

Closing of sale to Procter & Gamble at a cash purchase price of € 3.4 billion completed Successful completion allows Merck to further focus on innovation driven businesses in Healthcare, Life Science and Performance Materials Transaction successfully closed within an ambitious timeframe … Read the full press release

Merck to establish an innovation hub in Guangzhou, China

PRESS RELEASE -- 14, November 2018

Merck today (12 NOV 2018) signed an agreement with the Guangzhou Development District on innovation development in Southern China. DARMSTADT, Germany / GUANGZHOU, China, 14-Nov-2018 — /EuropaWire/ — Merck, the vibrant science and technology company, today signed an agreement with the … Read the full press release

AstraZeneca and Merck & Co., Inc. announce positive results from the randomised, double-blinded, placebo-controlled, Phase III SOLO-1 trial of Lynparza (olaparib) tablets

PRESS RELEASE -- 28, June 2018

Lynparza met primary endpoint of progression-free survival in women with BRCA-mutated advanced ovarian cancer and showed a safety profile consistent with previous trials AstraZeneca and MSD’s Lynparza is the only PARP inhibitor to demonstrate significant activity in the 1st-line maintenance … Read the full press release

Chinese Patent Office issued patent for Merck’s CRISPR technology used in a genomic-integration method for eukaryotic cells

PRESS RELEASE -- 25, April 2018

Merck today (23 APR 2018) announced that the Chinese Patent Office has issued a notice granting Merck’s patent application for the company’s CRISPR technology used in a genomic-integration method for eukaryotic cells. Patent in China covers integration of an external … Read the full press release

H. Lundbeck A/S to acquire Prexton Therapeutics BV for EUR 100 million upfront and up to EUR 805 million in development and sales milestones paid later

PRESS RELEASE -- 20, March 2018

Lundbeck will make an upfront payment of EUR 100 million and the deal terms also include up to EUR 805 million in development, regulatory and sales milestones Foliglurax is a first-in-class treatment which entered clinical phase II testing in Parkinson’s … Read the full press release

Merck: EMD Serono, Pfizer Canada receive approval for BAVENCIO™ from Health Canada

PRESS RELEASE -- 26, February 2018

First Health Canada approved treatment for rare and aggressive type of skin cancer MISSISSAUGA, ON, 26-Feb-2018 — /EuropaWire/ — Merck, which operates as EMD Serono in the US and Canada, and Pfizer Canada Inc. announced that Health Canada has approved BAVENCIO™ … Read the full press release

Merck appoints Dirk Toepfer as new Chief Information Officer

PRESS RELEASE -- 26, January 2018

Toepfer joins from Metro Group, where he served as Head of the IT service company Metro Systems DARMSTADT, 26-Jan-2018 — /EuropaWire/ — Merck, a leading science and technology company, today announced that Dirk Toepfer will join the Group as the new … Read the full press release

AstraZeneca: Japan approval for Lynparza (olaparib) tablets for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer

PRESS RELEASE -- 22, January 2018

Lynparza is the first PARP inhibitor approved in Japan Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed ovarian cancer regardless of BRCA mutation status CAMBRIDGE, 22-Jan-2018 — /EuropaWire/ — AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, … Read the full press release

Merck: Grant for Growth Innovation (GGI) for 2017 winners announced in Washington, U.S.

PRESS RELEASE -- 19, September 2017

Not intended for US/Canada based media The presentation of the grants coincides with the 10th International Meeting of Pediatric Endocrinology The awards program supports advancements in the field of growth and growth disorders DARMSTADT, 19-Sep-2017 — /EuropaWire/ — Merck, a leading … Read the full press release

Sanofi files patent infringement suit against Merck Sharp & Dohme Corp. in US

PRESS RELEASE -- 10, August 2017

PARIS, 10-Aug-2017 — /EuropaWire/ — Sanofi announced today that it filed a patent infringement suit against Merck Sharp & Dohme Corp. (“Merck”) on August 8, 2017 in the United States District Court for the District of New Jersey. In its suit Sanofi … Read the full press release

Merck invests EUR 90 million in four sites in Germany, Switzerland and France

PRESS RELEASE -- 14, July 2017

Relocations to drive focus on sites in Darmstadt, Schnelldorf (Germany), Buchs (Switzerland) and Molsheim (France) Sequential implementation until the end of 2022 € 90 million investment. Net impact of approximately minus 200 positions over 5 years DARMSTADT, 13-Jul-2017 — /EuropaWire/ … Read the full press release

Merck Ventures forms immuno-oncology spin-out company Onctura SA in Geneva, Switzerland

PRESS RELEASE -- 21, June 2017

iOnctura is set up to develop a pipeline of assets targeting immunosuppression in the tumour microenvironment The company will progress its portfolio of assets seamlessly into clinical evaluation, in collaboration with one of its shareholders Cancer Research Technology (CRT) The … Read the full press release